Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Human Leukocyte Antigen Allele-Killer Cell Immunoglobulin-like Receptor Partners on Sexually Transmitted Human Immunodeficiency Virus Type 1 Infection.
Serrano-Rísquez C, Omar M, Rallón N, Benito JM, Gómez-Vidal A, Márquez FJ, Alján M, Rivero-Juárez A, Pérez-Valero I, Rivero A, Sinangil F, Saulle I, Biasin M, Clerici M, Forthal D, Saéz ME, Caruz A. Serrano-Rísquez C, et al. Among authors: sinangil f. J Infect Dis. 2024 Nov 15;230(5):e1077-e1081. doi: 10.1093/infdis/jiae436. J Infect Dis. 2024. PMID: 39208444 Free PMC article.
Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.
N'guessan KF, Machmach K, Swafford I, Costanzo MC, Wieczorek L, Kim D, Akapirat S, Polonis VR, Pitisuttithum P, Nitayaphan S, Gurunathan S, Sinangil F, Chariyalertsak S, Ake JA, O'connell RJ, Vasan S, Paquin-Proulx D. N'guessan KF, et al. Among authors: sinangil f. Front Immunol. 2024 Feb 13;15:1339727. doi: 10.3389/fimmu.2024.1339727. eCollection 2024. Front Immunol. 2024. PMID: 38420129 Free PMC article. Clinical Trial.
Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability.
Shubin Z, Stanfield-Oakley S, Puangkaew J, Pitisutthithum P, Nitayaphan S, Gurunathan S, Sinangil F, Chariyalertsak S, Phanuphak N, Ake JA, O'Connell RJ, Vasan S, Akapirat S, Eller MA, Ferrari G, Paquin-Proulx D; RV306 Study Group. Shubin Z, et al. Among authors: sinangil f. AIDS. 2023 Aug 1;37(10):1519-1524. doi: 10.1097/QAD.0000000000003611. Epub 2023 Jun 1. AIDS. 2023. PMID: 37260254 Free PMC article. Clinical Trial.
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.
Costanzo MC, Paquin-Proulx D, Schuetz A, Akapirat S, Shubin Z, Kim D, Wieczorek L, Polonis VR, Trinh HV, Rao M, Anenia H, Barrera MD, Boeckelman J, Nails B, Thapa P, Zemil M, Sacdalan C, Kroon E, Kaewboon B, Tipsuk S, Jongrakthaitae S, Gurunathan S, Sinangil F, Kim JH, Robb ML, Ake JA, O'Connell RJ, Pitisutthithum P, Nitayaphan S, Chariyalertsak S, Eller MA, Phanuphak N, Vasan S; RV306; RV328 study groups. Costanzo MC, et al. Among authors: sinangil f. JCI Insight. 2023 May 8;8(9):e167664. doi: 10.1172/jci.insight.167664. JCI Insight. 2023. PMID: 37154156 Free PMC article.
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
Huang Y, Seaton KE, Casapia M, Polakowski L, De Rosa SC, Cohen K, Yu C, Elizaga M, Paez C, Miner MD, Kelley CF, Maenza J, Keefer M, Lama JR, Sobieszczyk M, Buchbinder S, Baden LR, Lee C, Gulati V, Sinangil F, Montefiori D, McElrath MJ, Tomaras GD, Robinson HL, Goepfert P; NIAID-funded HIV Vaccine Trials Network (HVTN) 114 Study Team. Huang Y, et al. Among authors: sinangil f. Vaccine. 2021 Jul 30;39(33):4641-4650. doi: 10.1016/j.vaccine.2021.06.066. Epub 2021 Jul 3. Vaccine. 2021. PMID: 34229888 Free PMC article. Clinical Trial.
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Dawson P, Dhitavat J, Phonrat B, Akapirat S, Karasavvas N, Wieczorek L, Polonis V, Eller MA, Pegu P, Kim D, Schuetz A, Jongrakthaitae S, Zhou Y, Sinangil F, Phogat S, Diazgranados CA, Tartaglia J, Heger E, Smith K, Michael NL, Excler JL, Robb ML, Kim JH, O'Connell RJ, Vasan S; RV306 study group. Pitisuttithum P, et al. Among authors: sinangil f. Lancet HIV. 2020 Apr;7(4):e238-e248. doi: 10.1016/S2352-3018(19)30406-0. Epub 2020 Feb 6. Lancet HIV. 2020. PMID: 32035516 Free PMC article. Clinical Trial.
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.
Easterhoff D, Pollara J, Luo K, Janus B, Gohain N, Williams LD, Tay MZ, Monroe A, Peachman K, Choe M, Min S, Lusso P, Zhang P, Go EP, Desaire H, Bonsignori M, Hwang KK, Beck C, Kakalis M, O'Connell RJ, Vasan S, Kim JH, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Arthos J, Rao M, Joyce MG, Ofek G, Ferrari G, Haynes BF. Easterhoff D, et al. Among authors: sinangil f. JCI Insight. 2020 Jan 30;5(2):e131437. doi: 10.1172/jci.insight.131437. JCI Insight. 2020. PMID: 31996483 Free PMC article.
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
Easterhoff D, Pollara J, Luo K, Tolbert WD, Young B, Mielke D, Jha S, O'Connell RJ, Vasan S, Kim J, Michael NL, Excler JL, Robb ML, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Tartaglia J, Phogat S, Kepler TB, Alam SM, Wiehe K, Saunders KO, Montefiori DC, Tomaras GD, Moody MA, Pazgier M, Haynes BF, Ferrari G. Easterhoff D, et al. Among authors: sinangil f. J Virol. 2020 Jan 31;94(4):e01120-19. doi: 10.1128/JVI.01120-19. Print 2020 Jan 31. J Virol. 2020. PMID: 31776278 Free PMC article. Clinical Trial.
82 results